Optimized preparation of in situ forming microparticles for the parenteral delivery of vinpocetine

Chemical and Pharmaceutical Bulletin

Volumn 56, Issue 6, 2008, Pages 796-801

  Li, Jizhong ^a   Chen, Fei ^a   Hu, Chanjuan ^a   He, Ling ^a   Yan, Keshu ^a   Zhou, Liying ^a   Pan, Weisan ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Bioavailability; Formulation optimization; In situ forming microparticle system; Vinpocetine

Indexed keywords

POLYGLACTIN; POLYSORBATE 80; PROPYLENE GLYCOL; VINPOCETINE;

ANIMAL EXPERIMENT; ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PARTICLE SIZE; RAT; SCANNING ELECTRON MICROSCOPY;

ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CARRIERS; DRUG COMPOUNDING; EXCIPIENTS; INFUSIONS, PARENTERAL; LACTIC ACID; MALE; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID; RATS; RATS, WISTAR; SOLUBILITY; VINCA ALKALOIDS;

EID: 45749092121     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.56.796     Document Type: Article

References (28)

1. Subhan Z., Hindmarch L., Eur. J. Clin. Pharmacol., 28, 567-571 (1985).
2. Hindmarch I., Fuchs H. H., Erzigkei H., Int. Clin. Psychopharmacol., 6, 31-43 (1991).
3. Casnda E., Harcoss P., Bacsy Z., Drug Dev. Res., 14, 185-187 (1988).
4. Pudleiner P., Vereczkey L., Eur. J. Drug Metab. Pharmacokinet., 18, 317-321 (1993).
5. Rabaji-Siahboomi A. R., Bus. Brief Pharmatech., 2003, 181-184 (2003).
6. Qiu Y., Garren J., Sammara E., Cao G., Abraham C., Cheskin H. S., Engh K. R., J. Pharm. Sci., 92, 2317-2325 (2003).
7. Dunn R. L., English J. P., Cowsar D. R., Vanderbilt D. P., U.S. Patent 4938763 (1990).
8. Shively M. L., Bennett A. T., Coonts B. A., Renner W. D., Southard J. L., J. Controlled Release, 33, 237-243 (1995).
9. Wang L., Kleiner L., Venkatraman S., J. Controlled Release, 90, 345-354 (2003).
10. Brannon-Peppas L., Int. J. Pharm., 116, 1-9 (1995).
11. Herrman J., Bodmeier R., Int. J. Pharm., 126, 129-138 (1995).
12. Graham P. D., Brodbeck K. J., McHugh A. J., J. Controlled Release, 58, 233-245 (1999).
13. Jackson J. K., Zhang X., Llewelllen S., Hunter W. L., Burt H. M., Int. J. Pharm., 270, 185-198 (2004).
14. Cleland J. L., Daugherty A., Mrsny R., Curr. Opin. Biotech., 12, 212-219 (2001).
15. Kranz H., Bodmeier R., Int. J. Pharm. doi: 10.1016/j.ijpharm.2006. 09.033 (2006).
16. Luan X., Bodmeier R., Eur. J. Pharm., 58, 445-455 (2006).
17. Wang X., Yaowu Fenxi Zazhi, 15, 23-26 (1995).
18. Abd Elbary A., Foda N., El-Gazayerly O., El Khatib M., Anal. Lett., 35, 1041-1054 (2002).
19. Pudleiner P., Vereczkey L., Eur. J. Drug Metab. Pharmacokinet., 18, 317-321 (1993).
20. Chacon M., Berges L., Molpeceres J., Aberturas M. R., Guzman M., Int. J. Pharm., 141, 81-91 (1996).
21. Wu W., Cui G. H., Foreign Med. Sci. Sect. Pharm., 27, 292-298 (2000).
22. Brodbeck K. J., DesNoyer J. R., McHugh A. J., J. Controlled Release, 62, 333-344 (1999).
23. Grande R., Beitinger R., Schaltenbrand R., Braun W., Arzneim-Forsch, 39, 1599-1602 (1989).
24. Lohmann A., Dingler E., Sommer W., Arzneim.-Forsch., 42, 914-917 (1992).
25. Manucla T. M., Joap P. P., Henrique M. A., et al., J. Pharm. Biomed. Anal., 14, 617-622 (1996).
26. Vereczkey L., Pudleiner P., Pol. J. Pharmacol. Pharm., 39, 161-165 (1987).
27. Miskolczi P., Kozma K., Polgar M., Vereczkey L., Eur. J. Drug Metab. Pharmacokinet., 15, 1-5 (1990).
28. Zhang H., Yao M., Morrison R. A., Chong S., Arch. Pharm. Res., 26, 768-772 (2003).